Spring Bank Pharmaceuticals Inc Receives a Buy from Cantor Fitzgerald

In a report released yesterday, Elemer Piros from Cantor Fitzgerald maintained a Buy rating on Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH), with a price target of $32. The company’s shares closed yesterday at $14.42.

According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 46.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Global Blood Therapeutics, and Bellicum Pharmaceuticals.

Currently, the analyst consensus on Spring Bank Pharmaceuticals Inc is Strong Buy and the average price target is $38.50, representing a 167.0% upside.

In a report released today, Chardan Capital also maintained a Buy rating on the stock with a $45 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.93 and a one-year low of $10.75. Currently, Spring Bank Pharmaceuticals Inc has an average volume of 21.05K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spring Bank Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its pipeline include RIG-I & STING Agonists.